When does the keytruda patent expire?

The patent for Keytruda, also known as pembrolizumab, has a complex expiration timeline. The initial patent for pembrolizuda expired in 2022, and Merck & Co is no longer the exclusive patent holder [1].

As for keytruda specifically, there was a patent settlement on the injectable version of Pembrolizumab in 2024. According to this patent settlement it expires after 2024 for all countries covered under the settlement.

However, in the United States, patents on the injectable form of Keytruda are set to expire in 2033, while the patent on the oral form will expire in 2038, but according to patent law in the United States this data is not always entirely accurate, it might change [2]. For the most up-to-date information, visit DrugPatentWatch.com [3].

Sources:

1. https://www.merck.com/connections/newsroom/press-releases/2014/20140130.html
2. https://www.drugpatentwatch.com/patent/US10169544/
3. https://www.drugpatentwatch.com